Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease CHANCE(NMO) Study

Hümmert, Martin W.; Schöppe, Louisa M.; Bellmann-Strobl, Judith; Siebert, Nadja; Paul, Friedemann; Duchow, Ankelien; Pellkofer, Hannah; Kümpfel, Tania; Havla, Joachim; Jarius, Sven; Wildemann, Brigitte; Berthele, Achim; Bergh, Florian Then; Pawlitzki, Marc; Klotz, Luisa; Kleiter, Ingo; Stangel, Martin; Gingele, Stefan; Weber, Martin S.; Faiss, Jürgen H.; Pul, Refik; Walter, Annette; Zettl, Uwe K.; Senel, Makbule; Stellmann, Jan-Patrick; Häußler, Vivien; Hellwig, Kerstin; Ayzenberg, Ilya; Aktas, Orhan; Ringelstein, Marius; Schreiber-Katz, Olivia und Trebst, Corinna (2022): Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease CHANCE(NMO) Study. In: Neurology, Bd. 98, Nr. 11, E1184-E1196

Abstract

Background and Objectives To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Methods In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. Results Two hundred twelve patients (80% women, median age 50 [19-83] years, median disease duration 7 [0-43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0-8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for euro59,574 (95% CI 51,225-68,293 or US dollars [USD] 70,297, 95% CI 60,445-80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65-0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (rho = 0.56, 95% CI 0.45-0.65);in the EDSS score 6.5 to 8.5 subgroup, the mean annual costs were euro129,687 (95% CI 101,946-160,336 or USD 153,031, 95% CI 120,296-189,196). The HRQoL revealed a negative correlation to disease severity (rho = -0.69, 95% CI -0.76 to -0.61);in the EDSS score 6.5 to 8.5 subgroup, the EQ-5D-5L mean index value was 0.195 (95% CI 0.13-0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. Discussion These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0028-3878
• Sprache: Englisch